---
schema_version: "secwatch.filing_event.v1"
accession: "0001790340-23-000054"
form_type: "8-K"
ticker: "IMRX"
cik: "0001790340"
company_name: "Immuneering Corp"
filed_at: "2023-11-09T23:59:59+00:00"
generated_at: "2026-06-08T07:18:41.587870+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Immuneering Q3 net loss $0.43/share; Phase 2a for IMM-1-104 expanded to 5 arms

## Summary
- Net loss $12.6M ($0.43/sh) vs $12.8M ($0.49/sh) in Q3 2022.
- Cash $97.2M at Sept 30, 2023 ($105.5M at Dec 31, 2022); runway into 2025.
- Phase 1 dose evaluation of IMM-1-104 ~2/3 enrolled; no DLTs; Phase 2 dose recommendation expected early 2024.
- Phase 2a expanded to 5 arms: 3 monotherapy (PDAC, melanoma, NSCLC) and 2 combinations (mFOLFIRINOX, gem/nab-paclitaxel); first patient dosing early 2024.
- IND for IMM-6-415 on track for Q4 2023; Phase 1/2a to include RAS and RAF mutant disease.

## SEC filing metadata
- accession: 0001790340-23-000054
- form_type: 8-K
- ticker: IMRX
- cik: 0001790340
- company_name: Immuneering Corp
- filed_at: 2023-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1790340/000179034023000054/0001790340-23-000054-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1790340/000179034023000054/imrx-20231109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001790340-23-000054
- JSON: https://secwatch.observer/filing/0001790340-23-000054.json
- Plain text: https://secwatch.observer/filing/0001790340-23-000054.txt

## Key facts
- Earnings Releases
  Immuneering Corp reported for the quarter ended September 30, 2023 results: net income $12.6 million, EPS $0.43 per share.
  - Period: for the quarter ended September 30, 2023
  - Net income: $12.6 million
  - EPS: $0.43 per share
  - Result: reported results
  source text: Net loss attributable to common stockholders was $12.6 million, or $0.43 per share, for the quarter ended September 30, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1790340/000179034023000054/0001790340-23-000054-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.